Home › Funds › KENNEDY CAPITAL MANAGEMENT LLC › CPRX

KENNEDY CAPITAL MANAGEMENT LLC position in CPRX

CATALYST PHARMACEUTICALS INC

KENNEDY CAPITAL MANAGEMENT LLC reported holding 856,609 shares of CPRX (CATALYST PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$26.9M, representing 0.48% of its reported portfolio and ranking #43 among its reported holdings. KENNEDY CAPITAL MANAGEMENT LLC has disclosed CPRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)856.61K sh
Reported value held$26.92M
Portfolio Weight0.48%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How KENNEDY CAPITAL MANAGEMENT LLC's CPRX position evolved

KENNEDY CAPITAL MANAGEMENT LLC first disclosed a stake in CPRX in Q3 2023 at 636,366 shares (US$7.4M). The position peaked in Q1 2026 at 1,199,598 shares, worth US$29.7M. Across 12 filings, KENNEDY CAPITAL MANAGEMENT LLC increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 856,609 shares valued at US$26.9M — a reduction of -342,989 shares quarter over quarter.. Notable position changes include a 101% increase in Q1 2024, a 29% trim in Q2 2026.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 636.37K $7.44M New
Q4 2023 527.90K $8.87M Reduce
Q1 2024 1.06M $16.92M Add
Q2 2024 1.28M $19.77M Add
Q3 2024 1.04M $20.70M Reduce
Q4 2024 1.02M $21.24M Reduce
Q1 2025 1.06M $25.74M Add
Q2 2025 1.01M $21.91M Reduce
Q3 2025 1.06M $20.89M Add
Q4 2025 1.21M $28.23M Add
Q1 2026 1.20M $29.70M Reduce
Q2 2026 856.61K $26.92M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CPRX and 13F data

CPRX (CATALYST PHARMACEUTICALS INC) is a company whose sector is not yet classified in our data. 42 other funds we track also report a position in CPRX — the largest reported positions include GLAZER CAPITAL, LLC (US$113.2M), HBK INVESTMENTS L P (US$88.6M), NEXPOINT ASSET MANAGEMENT, L.P. (US$50.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CPRX

All CPRX fund holders →

FAQ

How long has KENNEDY CAPITAL MANAGEMENT LLC held CPRX?

KENNEDY CAPITAL MANAGEMENT LLC has disclosed CPRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is KENNEDY CAPITAL MANAGEMENT LLC's current position in CPRX?

As of Q2 2026, KENNEDY CAPITAL MANAGEMENT LLC holds 856.61K shares of CPRX (CATALYST PHARMACEUTICALS INC), valued at $26.92M, representing 0.48% of its reported portfolio and ranking #43.

Has KENNEDY CAPITAL MANAGEMENT LLC been buying or selling CPRX?

In the latest 13F filing (Q2 2026), KENNEDY CAPITAL MANAGEMENT LLC reduced its position in CPRX. The position peaked in Q1 2026 at 1.20M shares.

Which other funds hold CPRX?

Other major institutional holders of CPRX include GLAZER CAPITAL, LLC, HBK INVESTMENTS L P, NEXPOINT ASSET MANAGEMENT, L.P., among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.